Searched for
SALIX PHARMA
Alembic Pharma receives final approval from USFDA for generic Mesalamine extended-release capsulesThe approved drug is therapeutically equivalent to Salix Pharmaceuticals Inc's reference listed drug (RLD), Apriso extended-release capsule...- Lupin looking to enter new product segments, geographies: MD Nilesh GuptaIn order to consolidate its business globally, the Mumbai-based firm has already inked various agreements in the previous fiscal.
- Teva’s hostile bid for Mylan: Deal could open up a $2-billion opportunity for pharma companiesAccording to experts, there is a possibility that the fruition of the deal will open up a $2-billion opportunity for Indian generic pharma ...
- Lupin launches anti-bacterial Zaxine tablets in CanadaZaxine 550 mg (rifaximin) is a long-term antibiotic treatment drug for adults living with HE, a complication of liver disease (cirrhosis).
- Pharma in 2014: Deals worth billions and fines worth millionsRanbaxy, founded by the family of Malvinder and Shivinder Mohan Singh, was at the centre of most of the developments for major part of the ...
- 5 Pharma stocks that propelled BSE Healthcare to lifetime highDespite the concerns on import alerts from the USFDA and recent drug recalls, the pharma sector was one of the top performers in the last q...
- Continuously evaluating opportunities for tie-ups with large MNCs: Ramesh Swaminathan, Lupin'We do keep talking to various big pharma companies for various kinds of alliance. So potentially I cannot speak about any deal until it ac...
- What does Crofelemer approval mean for Glenmark?What does Crofelemer approval mean for Glenmark?
- Crofelemer approval a big positive for company: Glenn Saldanha, Glenmark Pharma"There is another $6 million that Salix is likely to pay us for the facility that we are working on for the supplies of Crofelemer."
- Glenmark Pharmaceuticals to initiate filing for Crofelemer as Salix submits NDAGlenmark is going full steam ahead with the launch of Crofelemer post the issue of Napo Pharma's claim of termination of the deal.
- Napo termination will not impact company: GlenmarkIn an interview with ET Now, Glenn Saldanha, Chairman and Managing Director, Glenmark, gives his views on the company's strategies. Excerpt...
- Glenmark Pharma: Miles to go before new drug makes a markGlenmark’s partners — US-based Napo Pharmaceuticals and Salix Pharmaceuticals — have announced completion of phase-III trials for the drug ...
- We continue to remain optimistic about R&D space: Glen SaldanhaGlen Saldanha, Managing Director & CEO, Glenmark Pharmaceuticals speaks to ET Now. Excepts from the interview.
- ICICI Venture buys out US R&D firmICICI Venture has made the first buyout by an Indian private equity firm in the international market.
Load More
